XINT — Xintela AB Share News
0.000.00%
Last trade - 00:00- SEK200.68m
- SEK190.89m
- SEK2.28m
Brief: Xintela Q2 EPS at SEK -0.02
Brief: Xintela Extends Clinical Study With Xstem On Knee Osteoarthritis Patients
Brief: Xintela Q4 EPS at SEK -0.03
Brief: Xintela Q4 Loss Before Tax Widens To Tsek 12,175
Brief: Xintela Preclinical Study Results Indicate Disease Modifying Effect Of EQSTEM
Brief: Xintela Q3 Oper Loss Narrows To SEK 12.3 Million
Brief: Xintela Q3 EPS SEK -0.02
Brief: Xintela Stem Cell Product Assessed As Safe In Study
Brief: Xintela Says Its Clinical Phase I/IIa Study In Patients With Knee Osteoarthritis Is Progressing Very Well
Brief: Xintela Q2 EPS at SEK -0.06
Brief: Xintela Gets Product Patent In USA For Chondrocyte-Based Products
Brief: Xintela Extends Subscription Period In Ongoing Rights Issue
Brief: Xintela Publishes Positive Preclinical Results From XSTEM Treatment Of ARDS
Brief: Xintela Q1 Pretax Loss Narrows To SEK 15.8 Mln
Brief: Xintela Q1 EPS at SEK -0.05
Brief: Xintela Carries Out Rights Issue Of Units Of About SEK 123 Mln
Brief: Xintela Q4 Pretax Loss Widens To SEK 23.4 Million
Brief: Xintela, NorthX Biologics Sign Collaboration Framework Agreement
Brief: Xintela Obtains U.S. Patent For Stem Cell Treatment